The GPALPP1 Knockout NCI-H1975 Polyclonal Cells product consists of a heterogeneous population of NCI-H1975 lung adenocarcinoma cells subjected to CRISPR/Cas9-mediated disruption of the GPALPP1 gene. This polyclonal knockout pool provides a biologically relevant model system for loss-of-function studies without single-cell clonal selection. By eliminating GPALPP1 expression across a diverse cellular background, researchers can assess gene function while preserving the inherent genetic complexity of the host line. The product is designed for direct use in downstream assays, enabling robust and reproducible interrogation of GPALPP1-dependent phenotypes in a disease-relevant context.
The NCI-H1975 cell line is a lung adenocarcinoma epithelial model from a non-smoking female, harboring EGFR T790M and L858R mutations. It serves as a standard system for studying acquired resistance to EGFR tyrosine kinase inhibitors, EGFR-driven signaling, and metastatic progression. This well-characterized background provides an ideal context for examining how GPALPP1 knockout modulates oncogenic pathways and drug sensitivity.
GPALPP1 is a predicted phosphotransferase that may transfer phosphate groups within signaling cascades governing cell proliferation and survival. It likely participates in phosphorylation-dependent networks downstream of EGFR or serum growth factors. Putative pathways include PI3K/AKT and MAPK/ERK, with key players AKT, ERK, and CDK1. Downstream targets remain uncharacterized but may encompass cell cycle regulators such as Cyclin B1 and apoptotic factors. GPALPP1 knockout in NCI-H1975 cells allows dissection of its modulatory role in these phosphorylation networks and cancer-relevant outputs.
Knocking out GPALPP1 in NCI-H1975 cells provides a powerful model to study its intersection with EGFR-driven oncogenesis. As these cells depend on mutant EGFR, loss of GPALPP1 may uncover regulatory nodes that sustain viability or mediate TKI resistance. The polyclonal population captures diverse editing events, potentially revealing phenotypic heterogeneity linked to drug tolerance. This system supports translational efforts to identify vulnerabilities in EGFR-mutant lung cancer.
These polyclonal knockout cells are amenable to diverse functional assays, including proliferation (MTS/CCK-8), phospho-protein profiling (western blot for AKT, ERK), cell cycle and apoptosis analysis (flow cytometry with Annexin V), colony formation, migration, and RNA-seq transcriptomics. The model is particularly useful for drug target validation and investigating EGFR TKI resistance mechanisms. For further information, contact Ascent Research.
